Skip to content

AptarGroup ATR Depreciation

Depreciation at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Baxter International logo
Baxter InternationalBAX

Other financials

Income statement

See full
Revenue$982.9M+10.8%
Gross profit$351.9M+4.6%
Operating income$107.5M-5.2%
Net income$72.7M-7.8%
EPS (diluted)$1.12-4.3%

Balance sheet

See full
Cash & equivalents$225.0M+78.8%
Total debt$1.4B+32.7%
Total equity$2.6B+3.6%
Total assets$5.1B+12.6%

Cash flow

See full
Operating cash flow$118.7M+43.5%
CapEx$65.4M+15.0%
Free cash flow$53.3M+106%

Valuation

See full
Market cap$7.68B-17.9%
Enterprise value$8.89B-13.9%
P/E19.9×-5.4×
P/S-0.6×

Profitability

See full
Gross margin36.7%-1.6pp
Operating margin12.8%-1.2pp
Net margin10%-0.4pp
FCF margin8.4%-2.1pp

Returns & leverage

See full
Return on equity15%-0.2pp
Debt / equity0.5×+0.1×
Current ratio1.7×+0.4×

Where this comes from

Reported directly by AptarGroup in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: AptarGroup’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about AptarGroup's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AptarGroup's depreciation?
AptarGroup (ATR) reported depreciation of $64.31M in Q1 2026.
How has AptarGroup's depreciation changed year-over-year?
AptarGroup's depreciation increased by 17.1% year-over-year, from $54.9M to $64.31M.
What is the long-term trend for AptarGroup's depreciation?
Over 4 years (2021 to 2025), AptarGroup's depreciation has grown at a 5.7% compound annual growth rate (CAGR), from $193.78M to $242.31M.